RT Journal Article
SR Electronic
T1 Circulating Tumor Cells in Solid Tumor in Metastatic and Localized Stages
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4839
OP 4843
VO 29
IS 11
A1 MAESTRO, LUISA M.
A1 SASTRE, JAVIER
A1 RAFAEL, SARA B.
A1 VEGANZONES, SILVIA B.
A1 VIDAURRETA, MARTA
A1 MARTÍN, MIGUEL
A1 OLIVIER, CARLOS
A1 DE LA ORDEN, VIRGINIA B.
A1 GARCIA-SAENZ, JOSE ANGEL
A1 ALFONSO, ROSARIO
A1 ARROYO, MANUEL
A1 DIAZ-RUBIO, EDUARDO
YR 2009
UL http://ar.iiarjournals.org/content/29/11/4839.abstract
AB The aim of this study was the detection of circulating tumor cells (CTC) in three tumor types of epithelial origin. Patients and Methods: Four hundred and thirty-eight patients with breast cancer (56.2% localized and 43.8% metastatic), 195 with colorectal tumors (84.1% localized and 15.9% metastatic) and 50 with prostate cancer (52% localized and 48% metastatic) took part in this study. CTC quantification was performed using the CellSpotter Analyzer (Veridex® LLC). Results: 31.5% of patients with cancer had ≥2 CTCs/7.5 mL but none of the healthy volunteers were above this level (p<0.001). Among patients with metastatic disease, 62.3% of them had ≥2 CTCs/7.5 mL but only 14.0% of those with localized disease were above this level (p<0.001). The presence of CTCs were correlated to stage in the three studied tumor types and no differences in the number of cells were found between them. Conclusion: The presence of more than 2 CTCs/7.5 ml is a frequent event in metastatic cases. In particular, patients with localized disease who have more than 2 CTCs/7.5 ml should be carefully studied to determine the possible prognostic and predictive value of this finding.